MAPT and Alzheimer disease: To our knowledge, this is the first study analyzing Aβ1-42, APP-CTF, and p-tau in tear samples of a cohort of fully characterized AD patients according to the NIA-AA criteria and comparing biomarkers’ concentrations with an age- and sex-matched control group selected according to strict systemic and ocular inclusion criteria.